Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04077099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04077099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 7, 2020
Completion date
July 6, 2027
Enrollment
95 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc